Novartis, Alnylam to Work Together to Develop Liver Medicine
This article is for subscribers only.
Novartis AG agreed to work with Alnylam Pharmaceuticals Inc. to develop a treatment that can restore liver function and offer an alternative to transplants.
The U.S. biotech company’s technology will be used to inhibit a target identified by Novartis researchers, the Swiss company said Thursday, without disclosing financial details.